

Amendments to the Claims:

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A pharmaceutical composition comprising a nanoparticle and any one of a peptide, a polysaccharide, or a glycoprotein, attached electrostatically thereto, and a pharmaceutically acceptable carrier; or
a pharmaceutical composition comprising nanoparticles of
i) an admixture of mono-, di-, and tri-glycerides with
free polyethylene glycol and with mono-, and di-fatty
acid esters of polyethylene glycol, ii) sodiumdocusate,
and iii) glatiramer acetate; or
the pharmaceutical composition in lyophilized form.

2-58. (Canceled)

59. (Original) A method of inhibiting enzymatic degradation of a peptide, a polysaccharide, or a glycoprotein upon oral ingestion of the peptide, the polysaccharide, or the glycoprotein by an animal, comprising electrostatically attaching the peptide, the polysaccharide, or the glycoprotein to a nanoparticle prior to the oral ingestion, so as to thereby inhibit enzymatic degradation of the peptide, the polysaccharide, or the glycoprotein upon oral ingestion.

60-77. (Canceled)

Applicants: Vered Rosenberger, et al.

U.S. Serial No.: ~~10/577,500~~ 10/577,182

Filed: October 28, 2004

Page 3

78. (Currently Amended) A method of treating a subject afflicted with relapsing remitting multiple sclerosis, an autoimmune disease, or an inflammatory non-autoimmune disease, which comprises oral administration of a nanoparticulate formulation of glatiramer acetate, wherein the amount of glatiramer acetate in the nanoparticulate formulation is effective to alleviate a symptom of the relapsing-remitting multiple sclerosis, an autoimmune disease, or an inflammatory non-autoimmune disease in the subject.

79-88. (Canceled)

89. (New) A process for preparing the pharmaceutical composition of claim 1 comprising

- i) forming a spontaneous microemulsion by heating to above 50°C a mixture of water, and a wax;
- ii) cooling the microemulsion to room temperature to form nanoparticles; and
- iii) contacting the nanoparticles with the peptide, the polysaccharide, or the glycoprotein to form the pharmaceutical composition.

90. (New) A method of delivering to a subject adeoxyribonucleic acid molecule or a ribonucleic acid molecule, comprising administering to the subject a pharmaceutical composition comprising

the deoxyribonucleic acid molecule or the ribonucleic acid molecule attached electrostatically to a nanoparticle, and

a pharmaceutically acceptable carrier,

wherein the administration is oral or sublingual.